Company news
DiagnosTear Technologies, Inc. news in 2026
DiagnosTear Technologies, Inc.'s news releases, calls and decks from 2026, newest first.
DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx(TM) Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctivitis
September 10, 2026
DiagnosTear Technologies Announces FDA Pre-Submission for TeaRx(TM) Red Eye Diagnostic Test
September 3, 2026
DiagnosTear Technologies Inc. Announces Private Placement of Units
August 31, 2026
DiagnosTear Announces Interim Clinical Study Results Demonstrating Excellent Correlation Between TeaRx(TM) Red Eye and Quantitative ELISA Testing
July 9, 2026
DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx(TM) Clinical Study in Current Eye Research Journal
June 5, 2026
DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics
May 12, 2026
DiagnosTear Technologies Inc. Announces Results of AGM
May 7, 2026
DiagnosTear Technologies Inc. Announces Warrant Extension
May 4, 2026
DiagnosTear Technologies Inc. Announces Adoption of Semi-Annual Reporting
April 21, 2026
DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye
February 26, 2026
DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical
February 20, 2026
DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India
January 22, 2026
DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye
January 15, 2026